Logo image of CLSN

CELSION CORP (CLSN) Stock Fundamental Analysis

USA - NASDAQ:CLSN - US15117N6022 - Common Stock

1.96 USD
0 (0%)
Last: 9/20/2022, 8:01:31 PM
1.96 USD
0 (0%)
After Hours: 9/20/2022, 8:01:31 PM
Fundamental Rating

1

CLSN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. CLSN may be in some trouble as it scores bad on both profitability and health. CLSN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CLSN has reported negative net income.
CLSN Yearly Net Income VS EBIT VS OCF VS FCFCLSN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -5M -10M -15M -20M

1.2 Ratios

Industry RankSector Rank
ROA -40.03%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLSN Yearly ROA, ROE, ROICCLSN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -100 -200 -300

1.3 Margins

The Operating Margin and Gross Margin are not available for CLSN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) -5229.82%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLSN Yearly Profit, Operating, Gross MarginsCLSN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 -1K -2K -3K -4K

More info and screens

3

2. Health

2.1 Basic Checks

CLSN does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLSN has less shares outstanding than it did 1 year ago.
The debt/assets ratio for CLSN has been reduced compared to a year ago.
CLSN Yearly Shares OutstandingCLSN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M
CLSN Yearly Total Debt VS Total AssetsCLSN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -7.47, we must say that CLSN is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of 0.13 indicates that CLSN is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -7.47
ROIC/WACCN/A
WACC10.77%
CLSN Yearly LT Debt VS Equity VS FCFCLSN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 6.52 indicates that CLSN has no problem at all paying its short term obligations.
CLSN has a Quick Ratio of 6.52. This indicates that CLSN is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 6.52
Quick Ratio 6.52
CLSN Yearly Current Assets VS Current LiabilitesCLSN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for CLSN have decreased strongly by -35.02% in the last year.
The Revenue has decreased by -2.91% in the past year.
EPS 1Y (TTM)-35.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.33%
Revenue 1Y (TTM)-2.91%
Revenue growth 3Y0%
Revenue growth 5Y0%
Sales Q2Q%0%

3.2 Future

Based on estimates for the next years, CLSN will show a small growth in Earnings Per Share. The EPS will grow by 5.59% on average per year.
The Revenue is expected to decrease by -22.71% on average over the next years. This is quite bad
EPS Next Y21.32%
EPS Next 2Y11.03%
EPS Next 3Y14.57%
EPS Next 5Y5.59%
Revenue Next Year0%
Revenue Next 2Y-29.29%
Revenue Next 3Y-20.63%
Revenue Next 5Y-22.71%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CLSN Yearly Revenue VS EstimatesCLSN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 100K 200K 300K 400K 500K
CLSN Yearly EPS VS EstimatesCLSN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLSN. In the last year negative earnings were reported.
Also next year CLSN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLSN Price Earnings VS Forward Price EarningsCLSN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.03
CLSN Per share dataCLSN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 -6

4.3 Compensation for Growth

CLSN's earnings are expected to grow with 14.57% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.03%
EPS Next 3Y14.57%

More info and screens

0

5. Dividend

5.1 Amount

CLSN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELSION CORP

NASDAQ:CLSN (9/20/2022, 8:01:31 PM)

After market: 1.96 0 (0%)

1.96

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-15 2022-08-15/bmo
Earnings (Next)11-14 2022-11-14
Inst Owners0.31%
Inst Owner Change0%
Ins Owners37.95%
Ins Owner Change0%
Market Cap13.91M
Analysts82.5
Price Target27.54 (1305.1%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 27.83
P/FCF N/A
P/OCF N/A
P/B 0.3
P/tB N/A
EV/EBITDA 1.03
EPS(TTM)-7.21
EYN/A
EPS(NY)-4.23
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.07
BVpS6.63
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.03%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -5229.82%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.52
Quick Ratio 6.52
Altman-Z -7.47
F-Score2
WACC10.77%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.33%
EPS Next Y21.32%
EPS Next 2Y11.03%
EPS Next 3Y14.57%
EPS Next 5Y5.59%
Revenue 1Y (TTM)-2.91%
Revenue growth 3Y0%
Revenue growth 5Y0%
Sales Q2Q%0%
Revenue Next Year0%
Revenue Next 2Y-29.29%
Revenue Next 3Y-20.63%
Revenue Next 5Y-22.71%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A